# A Phase 1b Study Evaluating AMG 232 Alone and in Combination With Trametinib in Acute Myeloid Leukemia

> **NCT02016729** · PHASE1 · COMPLETED · sponsor: **Kartos Therapeutics, Inc.** · enrollment: 36 (actual)

## Conditions studied

- Advanced Malignancy
- Cancer
- Oncology
- Oncology Patients
- Acute Myeloid Leukemia

## Interventions

- **DRUG:** AMG 232
- **DRUG:** Trametinib

## Key facts

- **NCT ID:** NCT02016729
- **Lead sponsor:** Kartos Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-04-01
- **Primary completion:** 2017-04-19
- **Final completion:** 2017-07-31
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2019-02-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02016729

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02016729, "A Phase 1b Study Evaluating AMG 232 Alone and in Combination With Trametinib in Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT02016729. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*